Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...

Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ ... today announced a poster presentation at the 20 th Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 19 ...

today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo ...

DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today announced that the company will be ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...